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Dear Dr Martelletti,
Similar to Dr Hagen and colleagues
[1] in The Journal of Headache and
Pain, we were intrigued by the observa-
tion that genetic variants influence pain
sensitivity in humans [2]. The enzyme
catechol-O-methyltransferase (COMT)
degrades catecholamines including
dopamine. The functional variant of
COMT, Val158Met, determines COMT
enzyme activity, with the Met variant
leading to a 3–4-fold lower enzyme
activity, compared to the Val variant. The
finding that the Val158Met genotype
influences experimental pain sensitivity
[2] led us to query whether this variant
may contribute to the polygenic aetiolo-
gy of migraine. The COMT activity of
the genotypes is paralleled by the pain
threshold, being lowest in met/met,
intermediate in met/val and highest in
val/val [2]. We assessed a sample of 92
patients with migraine with aura, 127
patients with migraine without aura and
144 headache-free controls. Inclusion
and exclusion criteria were as described
previously [3]. Val158Met genotypes
were in Hardy-Weinberg equilibrium for
the patient and control groups. The fre-
quency of the met/met genotype was
25% in migraine with aura, 23.6% in
migraine without aura and 28.5% in
controls. Conversely, val/val frequency
was 30.4% in migraine with aura, 27.6%
in migraine without aura and 25.7% in
controls. There were no significant dif-
ferences between groups as assessed by
logistic regression, adjusted for sex dif-
ferences (migraine with aura: Wald
χ2=0.86, 2 degrees of freedom, p=0.65;
migraine without aura: Wald χ2=0.51, 2
degrees of freedom, p=0.77). Thus, simi-
lar to the finding of Dr Hagen and col-
leagues in this journal, we do not find a
contribution of the functional Val158Met
variant of the COMT gene to the patho-
genesis of migraine. This variant may be
more important in tumour pain [4] and
in tension headache [1] than in neuro-
pathic pain [5] or in migraine.
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